BioStructures Receives FDA 510(k) Clearance for Signafuse Bioactive Bone Graft Putty

 
BioStructures announced the U.S. Food and Drug Administration has granted 510(k) clearance for Signafuse Bioactive Bone Graft Putty. 

Advertisement

Signafuse is indicated for the posterolateral spine, extremities and pelvis as well as a bone graft extender in the posterolateral spine. It is comprised of a biphasic mineral and bioactive glass suspended in a resorbable polymer carrier.

 

BioStructures is a privately held orthobiologics company.

More Articles on Devices:

Medtronic 3Q Spine Revenues Up, BMP Continues Slump
OrthAlign Signs Exclusive Distribution Agreement With Biomet Japan for KneeAlign
Is Biomet Next to Form IPO?

 

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.